Ascentage Pharma Group International (OTCMKTS:ASPHF) is a clinical-stage biopharmaceutical company headquartered in Beijing, China, with a strategic presence in the United States. The company focuses on the discovery and development of targeted small-molecule therapies that modulate programmed cell death, leveraging a deep understanding of the Bcl-2 family of proteins.
Ascentage’s core activities center on the research and development of apoptosis regulators, including both Bcl-2 selective and dual Bcl-2/Bcl-xL inhibitors. Its diverse pipeline comprises several compounds in various stages of clinical and preclinical evaluation, addressing both hematological malignancies and solid tumors. The company’s R&D operations integrate proprietary chemistry platforms with translational biology to accelerate the progression of novel candidates through global regulatory pathways.
The company serves markets across Greater China, North America, and Singapore, collaborating with contract research organizations and academic institutions worldwide. Through partnerships and strategic alliances, Ascentage aims to expand its clinical footprint and optimize trial execution, particularly for oncology indications with significant unmet medical needs.
Founded in 2010 by a team of life science researchers, Ascentage has grown under a management team of industry veterans with extensive experience in drug discovery and development. This leadership combines academic insights with pharmaceutical expertise to drive innovation and establish the company as a global player in oncology therapeutics.
AI Generated. May Contain Errors.
